Group 1 - The core viewpoint highlights the competitive advantages of Chinese CXO companies in the chemical pharmaceutical sector, particularly in talent, chemical capabilities, compliance production capacity, and intellectual property protection, which are expected to maintain a strong irreplaceability over the next five years [1] - In the biopharmaceutical sector, the revenue growth rate of CDMO companies in South Korea and Japan is higher compared to domestic counterparts, while global competition includes companies from the US and Europe, with WuXi AppTec's market share in the CRDMO field continuing to rise [1] - Two long-term factors to observe include the potential structural limitations on overseas orders for Chinese companies due to the global biopharmaceutical supply chain restructuring driven by the "biopharmaceutical alliance," and the impact of the implementation of the "Biological Safety Law" on the international business of Chinese CXO companies [1] Group 2 - The Innovation Drug ETF Guotai (517110) tracks the SHS Innovation Drug Index (931409), which selects innovative pharmaceutical companies from the Shanghai, Shenzhen, and Hong Kong markets, covering both biopharmaceuticals and chemical pharmaceuticals [2] - The index focuses on companies with outstanding R&D capabilities and excellent growth potential, reflecting the overall performance of the innovative drug industry with a significant growth-oriented investment style [2]

Group 1 - The core viewpoint is that the chemical CDMO sector in China has significant advantages in talent, chemical capabilities, compliance capacity, and intellectual property protection, making it irreplaceable in the next five years [1] - The biopharmaceutical CDMO sector shows a clear industry beta, with companies in South Korea and Japan experiencing higher revenue growth compared to domestic firms, while the domestic leader WuXi AppTec is increasing its global market share in the CRDMO field [1] - The implementation of the Biological Safety Act is expected to lead to a valuation recovery in the CXO sector, indicating a long-term positive trend in China's innovative drug industry, particularly highlighted by explosive growth in BD transactions [1] Group 2 - The ETF Guotai (589720) tracks the Sci-Tech Innovation Drug Index (950161), which focuses on innovative R&D companies in the biopharmaceutical and chemical pharmaceutical sectors, reflecting the performance of growth-oriented companies driven by technological innovation in China's pharmaceutical industry [2]

Group 1 - The core viewpoint is that the chemical CDMO sector in China is gaining market attention due to its comprehensive advantages in talent, chemical capabilities, compliance production capacity, and intellectual property protection [1] - Chinese companies are expected to maintain a strong irreplaceable position in the chemical CDMO field over the next five years, especially compared to European and Indian counterparts [1] - In the biopharmaceutical CDMO sector, companies from South Korea and Japan are experiencing higher revenue growth than domestic firms, while WuXi AppTec is increasing its global market share in the XDC CRDMO field [1] Group 2 - The Guotai Innovation Drug ETF (589720) tracks the Science and Innovation Drug Index (950161), which includes listed companies involved in biopharmaceuticals and chemical pharmaceuticals, focusing on those with high R&D investment and strong innovation capabilities [2] - The index has a daily price fluctuation limit of 20%, reflecting the overall performance and development trends of China's new drug R&D industry [2] - The implementation of the Biosecurity Act is expected to lead to a valuation recovery in the CXO sector, while long-term attention is needed on the global biopharmaceutical supply chain restructuring process and the impact of regulatory details [1]